BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 30861111)

  • 21. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.
    Smith AE; Mohamedali AM; Kulasekararaj A; Lim Z; Gäken J; Lea NC; Przychodzen B; Mian SA; Nasser EE; Shooter C; Westwood NB; Strupp C; Gattermann N; Maciejewski JP; Germing U; Mufti GJ
    Blood; 2010 Nov; 116(19):3923-32. PubMed ID: 20693430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clonal Hematopoiesis and Risk of Progression of Heart Failure With Reduced Left Ventricular Ejection Fraction.
    Pascual-Figal DA; Bayes-Genis A; Díez-Díez M; Hernández-Vicente Á; Vázquez-Andrés D; de la Barrera J; Vazquez E; Quintas A; Zuriaga MA; Asensio-López MC; Dopazo A; Sánchez-Cabo F; Fuster JJ
    J Am Coll Cardiol; 2021 Apr; 77(14):1747-1759. PubMed ID: 33832602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Characteristics and Clinical Significance of Gene Mutation in Patients with Myelodysplastic Syndrome].
    Zhao F; Wang KL; Qin YT; Nilupar T; Patiguli A; Jiang M; Hao JP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Dec; 29(6):1864-1868. PubMed ID: 34893124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cryptic aberrations may allow more accurate prognostic classification of patients with myelodysplastic syndromes and clonal evolution.
    Svobodova K; Lhotska H; Hodanova L; Pavlistova L; Vesela D; Belickova M; Vesela J; Brezinova J; Sarova I; Izakova S; Lizcova L; Siskova M; Jonasova A; Cermak J; Michalova K; Zemanova Z
    Genes Chromosomes Cancer; 2020 Jul; 59(7):396-405. PubMed ID: 32170980
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.
    Steensma DP; Bejar R; Jaiswal S; Lindsley RC; Sekeres MA; Hasserjian RP; Ebert BL
    Blood; 2015 Jul; 126(1):9-16. PubMed ID: 25931582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Genetics of Myelodysplastic Syndromes: Clinical Relevance.
    Chiereghin C; Travaglino E; Zampini M; Saba E; Saitta C; Riva E; Bersanelli M; Della Porta MG
    Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clonal Hematopoiesis of Indeterminate Potential.
    Heuser M; Thol F; Ganser A
    Dtsch Arztebl Int; 2016 May; 113(18):317-22. PubMed ID: 27215596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pedigree investigation, clinical characteristics, and prognosis analysis of haematological disease patients with germline TET2 mutation.
    Wu X; Deng J; Zhang N; Liu X; Zheng X; Yan T; Ye W; Gong Y
    BMC Cancer; 2022 Mar; 22(1):262. PubMed ID: 35279121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Myeloid Clonal Infiltrate Identified With Next-Generation Sequencing in Skin Lesions Associated With Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: A Case Series.
    Martin de Frémont G; Hirsch P; Gimenez de Mestral S; Moguelet P; Ditchi Y; Emile JF; Senet P; Georgin-Lavialle S; Hanslik T; Maurier F; Adedjouma A; Abisror N; Mahevas T; Malard F; Adès L; Fenaux P; Fain O; Chasset F; Mekinian A
    Front Immunol; 2021; 12():715053. PubMed ID: 34671345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.
    Bejar R; Stevenson KE; Caughey B; Lindsley RC; Mar BG; Stojanov P; Getz G; Steensma DP; Ritz J; Soiffer R; Antin JH; Alyea E; Armand P; Ho V; Koreth J; Neuberg D; Cutler CS; Ebert BL
    J Clin Oncol; 2014 Sep; 32(25):2691-8. PubMed ID: 25092778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes.
    Abáigar M; Robledo C; Benito R; Ramos F; Díez-Campelo M; Hermosín L; Sánchez-Del-Real J; Alonso JM; Cuello R; Megido M; Rodríguez JN; Martín-Núñez G; Aguilar C; Vargas M; Martín AA; García JL; Kohlmann A; Del Cañizo MC; Hernández-Rivas JM
    PLoS One; 2016; 11(10):e0164370. PubMed ID: 27741277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.
    Bejar R; Stevenson KE; Caughey BA; Abdel-Wahab O; Steensma DP; Galili N; Raza A; Kantarjian H; Levine RL; Neuberg D; Garcia-Manero G; Ebert BL
    J Clin Oncol; 2012 Sep; 30(27):3376-82. PubMed ID: 22869879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utility of 5-Methylcytosine Immunohistochemical Staining to Assess Global DNA Methylation and Its Prognostic Impact in MDS Patients.
    Chandra D; Tyagi S; Singh J; Deka R; Manivannan P; Mishra P; Pati HP; Saxena R
    Asian Pac J Cancer Prev; 2017 Dec; 18(12):3307-3313. PubMed ID: 29286224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms.
    Pegliasco J; Hirsch P; Marzac C; Isnard F; Meniane JC; Deswarte C; Pellet P; Lemaitre C; Leroy G; Rabadan Moraes G; Guermouche H; Schmaltz-Panneau B; Pasquier F; Colas C; Benusiglio PR; Bera O; Bourhis JH; Brissot E; Caron O; Chraibi S; Cony-Makhoul P; Delaunay-Darivon C; Lapusan S; de Fontbrune FS; Fuseau P; Najman A; Vainchenker W; Delhommeau F; Micol JB; Plo I; Bellanné-Chantelot C
    Leukemia; 2022 Jan; 36(1):126-137. PubMed ID: 34172895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV portends a poor prognosis in myelodysplastic syndromes.
    Kaner JD; Thibaud S; Jasra S; Wang Y; Janakiram M; Sharma A; Sridharan A; Elias H; Polineni R; Assal A; Weiss L; Braunschweig I; Steidl U; Pradhan K; Shastri A; Chaitowitz M; Zingman B; Will B; Mantzaris I; Verma A
    Leuk Lymphoma; 2019 Dec; 60(14):3529-3535. PubMed ID: 31282240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Excellent Prognosis of Low-Risk Myelodysplastic Syndromes (MDS) Without Detectable Myeloid-Related Mutations.
    Polprasert C; Niparuck P; Rattanathammethee T; Chuncharunee S; Kobbuaklee S; Songserm K; Suksusut A; Trithiphen S; Lanamtieng T; Kongkiatkamon S; Chanswangphuwana C; Lawasut P; Bunworasate U; Rojnuckarin P
    Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e293-e299. PubMed ID: 34840089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted, Amplicon-Based, Next-Generation Sequencing to Detect Age-Related Clonal Hematopoiesis.
    Snetsinger B; Ferrone CK; Rauh MJ
    Methods Mol Biol; 2019; 2045():167-180. PubMed ID: 30941718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
    Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
    Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms.
    Chien KS; Ong F; Kim K; Li Z; Kanagal-Shamanna R; DiNardo CD; Takahashi K; Montalban-Bravo G; Hammond D; Sasaki K; Pierce SA; Kantarjian HM; Garcia-Manero G
    Cancer Med; 2024 Mar; 13(5):e7093. PubMed ID: 38497538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes.
    Hamilton BK; Rybicki L; Hirsch C; Przychodzen B; Nazha A; Gerds AT; Hanna R; Kalaycio M; Sekeres MA; Sobecks R; de Lima M; Majhail NS; Maciejewski J
    Bone Marrow Transplant; 2019 Aug; 54(8):1281-1286. PubMed ID: 30655603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.